<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Given evidence for the role of Src family kinases, especially Lyn kinase, in myeloblast proliferation and the in vitro inhibitory activity of <z:chebi fb="0" ids="49375">dasatinib</z:chebi> on Src and Lyn, we conducted a phase II study to assess overall response to 100mg/day <z:chebi fb="0" ids="49375">dasatinib</z:chebi> in patients with higher-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> arising from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and who had failed prior treatment with azanucleoside analogs </plain></SENT>
<SENT sid="1" pm="."><plain>Among 18 patients treated, 3 responded, 4 had stable disease, and 10 experienced disease progression </plain></SENT>
<SENT sid="2" pm="."><plain>Toxicities were limited and consistent with previous reports </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="49375">Dasatinib</z:chebi> appears to be safe but with limited efficacy </plain></SENT>
</text></document>